• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Germany·Healthcare·0PMJ.L
Share

Siemens Healthineers AG Stocks

€ 38.29Last Updated 11.09.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

€ 50.91B

€ 38.29
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Siemens Healthineers AG, operating through its various subsidiaries, is dedicated to the development, production, and worldwide distribution of a comprehensive portfolio of diagnostic and therapeutic solutions for healthcare professionals. The company's operations are structured across four primary segments: Imaging, Diagnostics, Varian, and Advanced Therapies. Within the Imaging segment, customers access advanced technologies such as magnetic resonance imaging (MRI), computed tomography (CT), X-ray systems, molecular imaging, and ultrasound equipment. The Diagnostics segment delivers a range of in-vitro diagnostic products and services, catering to laboratory, molecular, and point-of-care diagnostic needs, alongside specialized workflow solutions for laboratories and informatics tools. The Varian segment specializes in advanced cancer care technologies, providing a suite of solutions and services to oncology departments within hospitals and clinics. This includes optimized, technology-enabled workflows, comprehensive clinical and consulting services, and innovative digital applications designed for managing patient treatment and therapy pathways. For image-guided minimally invasive procedures in fields like cardiology, interventional radiology, and surgery, the Advanced Therapies segment offers specialized products. Its portfolio encompasses angiography systems, mobile C-arms, and an advanced robotic-assisted platform specifically engineered for endovascular coronary and peripheral vascular interventions. Beyond these core offerings, Siemens Healthineers also provides essential support services. These include equipment performance management, clinical education and e-learning programs, asset management, and outsourced departmental services for both laboratories and wider healthcare facilities, complemented by consulting and digital health services. The company's corporate headquarters are situated in Erlangen, Germany, and it operates as a subsidiary of Siemens Aktiengesellschaft.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.09.2026 00:58

Data from some Revolut customers was leaked

12.09.2026 16:01

Small caps last week: Chewy's earnings miss, Signet's best day ever, AE rethinks ads

12.09.2026 13:01

The iPhone Reboot, the AGI Era, and Silicon Valley's Right Turn

12.09.2026 05:06

Spam from OpenAI's AI agents disrupted the developer service for four days

12.09.2026 03:52

Citrini, the founder who spooked the market with his prediction of AI threats, has sold the company. What's next?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026